Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases
Our analysis shows that RZV vaccination prevents HZ in ≥50-year-old adults with selected AIDs, consistent with prior studies.
Authors
- Nathalie Servotte (ORCID: https://orcid.org/0000-0002-3330-6482)
- Dagna Constenla (ORCID: https://orcid.org/0000-0003-4935-1584)
- Hannah Alsdurf (ORCID: https://orcid.org/0000-0001-9801-7852)
- Agnes Mwakingwe-Omari (ORCID: https://orcid.org/0000-0002-6576-1981)
- Germain Lonnet
- Huifeng Yun (ORCID: https://orcid.org/0000-0002-0158-1797)
- Emmanuel Aris (ORCID: https://orcid.org/0000-0001-8640-1742)
- Ramsanjay Rk
Institutions
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (India) (IN)
- GlaxoSmithKline (United States) (US)
- National Blood Clot Alliance (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1093/infdis/jiaf395
- Citations
- 2
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.71